Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate)...
38 insider purchases on record · latest filing 2026-06-08.
Insiders have also filed 2 sale transactions at CING.